Drug Trial Radar · NCT01196260
Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and III
Last checked: Nov 19, 2026Latest source record: Feb 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
8,000
Planned (sponsor's estimate)
Start
Jan 2004
Primary completion
Dec 2020
Study completion Dec 2020
Sponsor
- Lead sponsor
- State Key Laboratory of Cancer BiologyResearch network
- Sponsor type
- Research network
- Collaborators
- Tianjin Union Medical Center; Beihua University; Chengdu Medical College; Shanghai Jiao Tong University School of Medicine
- First posted
- Sep 8, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will examine a new combination of drugs: Capecitabine and Oxaliplatin for the treatment of Stage II and III colorectal cancer. Capecitabine and Oxaliplatin are approved by the Food and Drug Administration (FDA) for use in colorectal cancer. The combination of drugs is experimental (not approved by the FDA as standard treatment), but is a widely used treatment option and preliminary studies have shown that treatment with the combination has a positive effect on metastatic colorectal cancer.
Conditions
- Colorectal Cancer
Interventions
Capecitabine and OxaliplatinDrug
Capecitabine and Oxaliplatin will be under the NSCLC guideline
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the objective response rate of patients with metastatic colorectal cancer received the combination of drugsTime frame: 7 years
- To determine the relapse of patients with metastatic colorectal cancer received the combination of drugsTime frame: 7 years
- To determine prognosis of patients with metastatic colorectal cancer received the combination of drugsTime frame: 7 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
State Key Laboratory of Cancer Biology
Xi'an, Shaanxi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.